한국의 알츠하이머병 환자에서 아세틸콜린 에스터레이스 억제제의 뇌척수액 베타아밀로이드 1-42 분획과 인산화타우단백 농도에 미치는 효과 (The Effect of Acetylcholine Esterase Inhibitor on Cerebrospinal Fluid β-Amyloid 1-42 and Phosphorylated Tau Protein in Korean Alzheimer’s Disease Patients: Preliminary Study)

서지정보

· 발행기관 : 대한신경과학회
· 수록지 정보 : 대한신경과학회지 / 26권 / 3호 / 224 ~ 230페이지
· 저자명 : 이은희, 윤영철, 박광열, 민주홍, 권오상, 이현옥, 홍현종

초록

Background: Alzheimer’s disease (AD) is characterized by the pathology of amyloid plaques and tau-associated neurofibrillary tangles. Acetylcholine esterase (AChE) transforms the β-amyloid monomer into an oligomer, and increases β-amyloid aggregation in the brain. Increased β-amyloid breaks the cytoskeleton of the brain by hyperphosphorylation of the tau protein. Previous studies support that AChE inhibitor has an inhibitory effect on toxicity of the β-amyloid and phophorylated tau protein. The purpose of this study was to analyze the CSF β-amyloid 1-42 (Aβ1-42) and phosphorylated tau protein in AD and determine their difference depending on whether AChE inhibitor was taken or not.
Methods: Subjects included 16 AD, 14 normal controls, and 15 disease controls. Nine of AD group had taken an AChE inhibitor while the remainder had not. The CSF Aβ1-42 and phosphorylated tau were measured by ELISA.
Results: The CSF Aβ1-42 levels were lower in AD patients than in other groups (p<0.01). We also found increased CSF Aβ1-42 levels in the AChE inhibitor users, compared with non-users.
Conclusions: The level of CSF Aβ1-42 may have a diagnostic value in the patients with cognitive impairments. Also, we may expect the effect of AChE inhibitor on Alzheimer’s pathology by measuring CSF Aβ1-42 levels. Therefore, the level of CSF Aβ1-42 may serve as a biological surrogate marker for AD treatment.

영어초록

Background: Alzheimer’s disease (AD) is characterized by the pathology of amyloid plaques and tau-associated neurofibrillary tangles. Acetylcholine esterase (AChE) transforms the β-amyloid monomer into an oligomer, and increases β-amyloid aggregation in the brain. Increased β-amyloid breaks the cytoskeleton of the brain by hyperphosphorylation of the tau protein. Previous studies support that AChE inhibitor has an inhibitory effect on toxicity of the β-amyloid and phophorylated tau protein. The purpose of this study was to analyze the CSF β-amyloid 1-42 (Aβ1-42) and phosphorylated tau protein in AD and determine their difference depending on whether AChE inhibitor was taken or not.
Methods: Subjects included 16 AD, 14 normal controls, and 15 disease controls. Nine of AD group had taken an AChE inhibitor while the remainder had not. The CSF Aβ1-42 and phosphorylated tau were measured by ELISA.
Results: The CSF Aβ1-42 levels were lower in AD patients than in other groups (p<0.01). We also found increased CSF Aβ1-42 levels in the AChE inhibitor users, compared with non-users.
Conclusions: The level of CSF Aβ1-42 may have a diagnostic value in the patients with cognitive impairments. Also, we may expect the effect of AChE inhibitor on Alzheimer’s pathology by measuring CSF Aβ1-42 levels. Therefore, the level of CSF Aβ1-42 may serve as a biological surrogate marker for AD treatment.

참고자료

· 없음